Free Trial

Travere Therapeutics (TVTX) Stock Price, News & Analysis

Travere Therapeutics logo
$21.11 +0.35 (+1.69%)
As of 03:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Travere Therapeutics Stock (NASDAQ:TVTX)

Key Stats

Today's Range
$20.15
$21.71
50-Day Range
$13.49
$21.40
52-Week Range
$5.79
$25.29
Volume
1.40 million shs
Average Volume
1.52 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.79
Consensus Rating
Moderate Buy

Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Travere Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

TVTX MarketRank™: 

Travere Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 577th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Travere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Travere Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Travere Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Travere Therapeutics are expected to grow in the coming year, from ($1.40) to ($0.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Travere Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Travere Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Travere Therapeutics has a P/B Ratio of 7.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    14.71% of the float of Travere Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Travere Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Travere Therapeutics has recently decreased by 4.41%, indicating that investor sentiment is improving.
  • Dividend Yield

    Travere Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Travere Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.71% of the float of Travere Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Travere Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Travere Therapeutics has recently decreased by 4.41%, indicating that investor sentiment is improving.
  • News Sentiment

    Travere Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Travere Therapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    Only 2 people have searched for TVTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,507,377.00 in company stock.

  • Percentage Held by Insiders

    Only 4.06% of the stock of Travere Therapeutics is held by insiders.

  • Read more about Travere Therapeutics' insider trading history.
Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TVTX Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
See More Headlines

TVTX Stock Analysis - Frequently Asked Questions

Travere Therapeutics' stock was trading at $17.42 at the start of the year. Since then, TVTX stock has increased by 17.7% and is now trading at $20.5030.
View the best growth stocks for 2025 here
.

Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its quarterly earnings results on Thursday, May, 1st. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.08. The firm's quarterly revenue was up 83.3% compared to the same quarter last year.
Read the conference call transcript
.

Travere Therapeutics' top institutional shareholders include Emerald Advisers LLC (2.34%), Emerald Mutual Fund Advisers Trust (1.26%), Assenagon Asset Management S.A. (0.47%) and Bank of New York Mellon Corp (0.26%). Insiders that own company stock include Eric M Dube, Steve Aselage, Peter Heerma, William E Rote, Christopher R Cline, Jula Inrig, Jeffrey A Meckler, Elizabeth E Reed, Sandra Calvin, Gary A Lyons, Laura Clague and Roy D Baynes.
View institutional ownership trends
.

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Home Depot (HD), Walmart (WMT), Netflix (NFLX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Company Calendar

Last Earnings
5/01/2025
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TVTX
Employees
460
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.79
High Stock Price Target
$47.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+50.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-111,400,000.00
Net Margins
-137.90%
Pretax Margin
-171.40%

Debt

Sales & Book Value

Annual Sales
$233.18 million
Price / Cash Flow
N/A
Book Value
$2.67 per share
Price / Book
7.91

Miscellaneous

Free Float
75,123,000
Market Cap
$1.87 billion
Optionable
Optionable
Beta
0.84
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:TVTX) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners